DEF 14A: INmune Bio Inc. Sets Date for Virtual Annual Stockholders Meeting

INmune Bio Inc. will hold its annual stockholders meeting virtually on July 19, 2024, to elect directors and ratify the appointment of its independent accounting firm.

Summary

• INmune Bio Inc. will conduct its annual stockholders meeting virtually on July 19, 2024, at 10:00 A.M. Eastern Time.
• Stockholders of record as of May 23, 2024, are eligible to vote on two key proposals.
• The first proposal involves the election of six directors to serve until the next annual meeting.
• The second proposal seeks to ratify the appointment of Marcum LLP as the company's independent registered public accounting firm for the year ending December 31, 2024.
• The Board of Directors recommends voting FOR both proposals.
• The meeting will be held virtually at www.virtualshareholdermeeting.com/INMB2024, where stockholders can participate, vote, and submit questions.
• As of the record date, May 23, 2024, there were 19,782,429 shares of common stock outstanding.
• A quorum requires 33.3% of the outstanding capital stock to be represented.
• Directors and executive officers held approximately 22.7% of the company's common stock as of the record date.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, presenting factual information about the upcoming annual meeting. The tone is neutral and professional, with a clear recommendation from the Board of Directors. The sentiment is moderately positive due to the routine nature of the information and the absence of any negative disclosures.

Positives

• The virtual meeting format allows for broader stockholder participation.
• The Board of Directors is actively engaged in corporate governance, as evidenced by the annual self-evaluation and committee reviews.
• The company has a Code of Ethics applicable to its principal executive officers and other employees.
• The Audit Committee is comprised of independent and financially literate members.
• The company has established three standing committees: Audit, Compensation, and Nominating and Corporate Governance.
• The company provides multiple avenues for stockholders to vote, including internet, phone, and mail.

Future Outlook

The document outlines the upcoming annual meeting and provides information necessary for stockholders to make informed decisions regarding the election of directors and ratification of the accounting firm. No specific forward-looking statements about the company's financial performance or operations are included.

Management Comments

• The Board of Directors recommends that you vote FOR the proposals set forth in this Notice of Annual Meeting of Stockholders and the Proxy Statement.

Industry Context

As a biotech company, INmune Bio's annual meeting and corporate governance practices are standard procedures. The election of directors and ratification of the accounting firm are routine matters. The virtual meeting format reflects a growing trend in corporate governance to enhance accessibility and reduce costs.

Comparison to Industry Standards

• The virtual annual meeting format is increasingly common among publicly traded companies, including biotech firms, to enhance accessibility and reduce costs.
• The composition of the Audit Committee, with members meeting independence and financial literacy requirements, aligns with best practices and regulatory standards.
• The disclosure of fees paid to the independent auditor is a standard practice, providing transparency to stockholders.
• The company's corporate governance policies, including the Code of Ethics and Insider Trading Policy, are consistent with industry norms and regulatory requirements.
• The level of detail provided in executive and director compensation disclosures is comparable to that of other publicly traded biotech companies of similar size.

Related Party Transactions

• The company paid UCL $573,000 and $586,000 in 2023 and 2022, respectively, for medical research; the Chief Scientific Officer is a professor at the University of London.
• The company paid AmplifyBio $77,000 and $230,000 in 2023 and 2022, respectively, for research and development; the CEO of AmplifyBio is on the Board of Directors of the Company.
• The company has an exclusive license agreement with Immune Ventures, LLC, owned by RJ Tesi, David Moss, and Mark Lowdell.
• The company recorded a $25,000 payable to Immune Ventures as of December 31, 2023, related to a Phase I trial with INKmune.

Stakeholder Impact

• Shareholders have the opportunity to influence the company's direction by voting on the election of directors and the ratification of the accounting firm.
• Employees are subject to the company's Code of Ethics and Insider Trading Policy.
• The company's relationships with UCL and AmplifyBio impact the progress of its research and development efforts.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold the virtual annual meeting on July 19, 2024.
• The company will announce preliminary voting results at the meeting and publish final results in a Current Report on Form 8-K.

Key Dates

Keywords

annual meeting, proxy statement, stockholders, directors, Marcum LLP, voting, corporate governance, INmune Bio Inc.